The Serametrix Immune Monitoring Package measures different elements of the immune system, delivering a comprehensive data set on humoral and cellular anti-tumor immunity in cancer patients. The package allows pharmaceutical companies to conduct immune monitoring studies on patients and identify those patients most likely to benefit from treatment.
The Serametrix Immune Monitoring Package includes study design, measurement of serum antibodies, T-cell response, and circulating myeloid derived suppressor cells (MDSCs), and results with comprehensive analysis and interpretation. Results from these three methods provide a rich picture of the relationship between immune activity and clinical benefit for the patients.
To discuss ideas for your study or request a quote, click here.